Novel Fusion Transcripts Associate with Progressive Prostate Cancer  by Yu, Yan P. et al.
The American Journal of Pathology, Vol. 184, No. 10, October 2014
AS
IP
20
14
AJ
P
CM
E P
rog
ramSee related Commentary on page 2608
TUMORIGENESIS AND NEOPLASTIC PROGRESSION
Novel Fusion Transcripts Associate with Progressive
Prostate Cancer
Yan P. Yu,* Ying Ding,y Zhanghui Chen,* Silvia Liu,y Amantha Michalopoulos,* Rui Chen,y Zulﬁqar G. Gulzar,z Bing Yang,x
Kathleen M. Cieply,* Alyssa Luvison,* Bao-Guo Ren,* James D. Brooks,z David Jarrard,x Joel B. Nelson,{
George K. Michalopoulos,* George C. Tseng,y and Jian-Hua Luo*
ajp.amjpathol.orgFrom the Departments of Pathology,* Biostatistics,y and Urology,{ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; the Department of
Urology,z Stanford University School of Medicine, Stanford, California; and the Department of Urology,x University of Wisconsin School of Medicine at
Madison, Madison, Wisconsin
CME Accreditation Statement: This activity (“ASIP 2014 AJP CME Program in Pathogenesis”) has been planned and implemented in accordance with the Essential Areas and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the
American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this journal-based CME activity (“ASIP 2014 AJP CME Program in Pathogenesis”) for a maximum of 48 AMA PRA Category 1 Credit(s). Physicians should
only claim credit commensurate with the extent of their participation in the activity.
CME Disclosures: The authors of this article and the planning committee members and staff have no relevant ﬁnancial relationships with commercial interests to disclose.Accepted for publicationC
P
hJune 30, 2014.
Address correspondence to
Jian-Hua Luo, M.D., Ph.D.,
Department of Pathology,
University of Pittsburgh School
of Medicine, 3550 Terrace St,
Scaife S-760, Pittsburgh,
PA 15261. E-mail: luoj@
upmc.edu.opyright ª 2014 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2014.06.025The mechanisms underlying the potential for aggressive behavior of prostate cancer (PCa) remain
elusive. In this study, whole genome and/or transcriptome sequencing was performed on 19
specimens of PCa, matched adjacent benign prostate tissues, matched blood specimens, and organ
donor prostates. A set of novel fusion transcripts was discovered in PCa. Eight of these fusion
transcripts were validated through multiple approaches. The occurrence of these fusion transcripts
was then analyzed in 289 prostate samples from three institutes, with clinical follow-up ranging
from 1 to 15 years. The analyses indicated that most patients [69 (91%) of 76] positive for any of
these fusion transcripts (TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017,
TMEM135-CCDC67, KDM4-AC011523.2, MAN2A1-FER, and CCNH-C5orf30) experienced PCa recurrence,
metastases, and/or PCa-speciﬁc death after radical prostatectomy. These outcomes occurred in only
37% (58/157) of patients without carrying those fusion transcripts. Three fusion transcripts
occurred exclusively in PCa samples from patients who experienced recurrence or PCaerelated
death. The formation of these fusion transcripts may be the result of genome recombination. A
combination of these fusion transcripts in PCa with Gleason’s grading or with nomogram signiﬁ-
cantly improves the prediction rate of PCa recurrence. Our analyses suggest that formation of
these fusion transcripts may underlie the aggressive behavior of PCa. (Am J Pathol 2014, 184:
2840e2849; http://dx.doi.org/10.1016/j.ajpath.2014.06.025)Supported by NIH grants RO1 CA098249 (J.-H.L.) and 1U01CA152737-
01 (J.D.B.), American Cancer Society grant RSG-08-137-01-CNE (Y.P.Y.),
and a University of Pittsburgh Cancer Institute grant.
Y.P.Y., Y.D., and Z.C. contributed equally to this work.
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this work.
Disclosures: None declared.Despite a high incidence,1,2 only a fraction of men diag-
nosed with prostate cancer (PCa) develop metastases and
even fewer die from the disease. Most prostate cancers
remain asymptomatic and clinically indolent. The precise
mechanisms for the development of progressive, clinically
relevant PCa remain elusive. Furthermore, the inability to
predict potential aggressiveness of PCa has resulted instigative Pathology.
.
Signature Fusion Genes for Prostate Cancersigniﬁcant overtreatment of the disease. The dichotomous
nature of PCada subset of life-threatening malignancies in
the larger background of histological alterations lacking the
clinical features implicit with that labeldis a fundamental
challenge in disease management.
To identify genome markers for PCa, tumor (T), adjacent
normal prostate tissue (AT), and peripheral blood (B) sam-
ples were obtained from ﬁve prostate cancer patients who
experienced recurrence with fast increase of prostate-
speciﬁc antigen doubling time (PSADT; <4 months). In
one patient, normal adjacent prostate tissue was not available
(Supplemental Table S1). For whole genome sequencing, an
average of 200 GB was sequenced per sample to achieve 33-
fold coverage of the entire genome. Total RNA from all T
and AT samples was sequenced to achieve >1333-fold
(average, 400 million reads per sample) coverage per gene.
Total RNA from four age-matched, entirely histologically
benign prostate tissues, harvested from organ donors, was
similarly sequenced as a tissue control. The sequencing data
were aligned to human reference genome HG19.3 Fusion
transcripts were then identiﬁed, ﬁltered, and validated. It was
our hypothesis that the presence of these fusion transcripts in
the primary tumor would be associated with disease recur-
rence, development of metastatic disease, or prostate can-
cerespeciﬁc death. Therefore, the fusion transcripts were
analyzed on 90 PCa samples from men with known clinical
outcomes and 10 benign prostates harvested at organ
donation. A prediction model for PCa recurrence and short
postoperative PSADT was built. This model was then
applied to 89 additional PCa samples from the University of
Pittsburgh Medical Center (UPMC; Pittsburgh, PA), 30
samples from Stanford University Medical Center (Stanford,
CA), and 36 samples from the University of Wisconsin
Madison Medical Center (Madison, WI), with follow-up
ranging from 1 to 15 years. A total of 127 of these samples
are from patients who experienced PCa recurrence after
radical prostatectomy, and 106 are from patients with no ev-
idence of recurrence for at least 5 years after the surgery. The
remaining 46 samples are from patients who had <5 years of
follow-up and had not yet experienced biochemical recur-
rence. The association of fusion transcript expression with
PCa recurrence was analyzed.
Materials and Methods
Tissue Samples
A total of 218 specimens of PCa, 4 matched ATs, 5 matched
Bs, and 14 organ donor prostates were obtained from the
University of Pittsburgh Tissue Bank in compliance with
institutional regulatory guidelines (Supplemental Tables S1
and S2). Procedures of microdissection of PCa samples and
DNA extraction were previously described.4e6 The pro-
tocols of tissue procurement and procedure were approved
by the Institution Board of Review of the University of
Pittsburgh. PCa samples of the Stanford University MedicalThe American Journal of Pathology - ajp.amjpathol.orgCenter cohort (Supplemental Table S3) and the University of
Wisconsin Madison Medical Center cohort (Supplemental
Table S4) were obtained from corresponding institutional
tissue banks and approved by Institutional Review Boards.
Information about PSADT and time to recurrence was not
available for the Wisconsin cohort.
Genome and Transcriptome Sequencing Library
Preparation and Sequencing
To prepare the genomic DNA libraries, 50 ng of DNA was
subjected to the tagmentation reactions using the NEXTERA
DNA sample prep kit (Madison, WI) for 5 minutes at 55C.
The DNA was then ampliﬁed with adaptor and sequencing
primers for nine cycles of the following procedure: 95C for
10 seconds, 62C for 30 seconds, and 72C for 3 minutes.
The PCR products were puriﬁed with Ampure beads
(Beckman-Coulter, Brea, CA). The quality of genomic DNA
libraries was then analyzed with quantitative PCR using
Illumina sequencing primers (Illumina, Inc., San Diego, CA)
and quantiﬁed with an Agilent 2000 bioanalyzer. For tran-
scriptome sequencing, total RNAwas extracted from prostate
samples using TRIzol, and treated with DNase1 (Life
Technologies, Grand Island, NY). Ribosomal RNA was then
removed from the samples using a RIBO-Zero Magnetic kit
(Epicentre, Madison, WI). The RNA was reverse transcribed
to cDNA and ampliﬁed using TruSeq RNA Sample Prep Kit
version 2 from Illumina, Inc. The library preparation process,
such as adenylation, ligation, and ampliﬁcation, was per-
formed following the manual provided by the manufacturer.
The quantity and quality of the libraries were assessed as
those described above. The procedure of 200-cycle paired-
end sequencing in Illumina HiSeq2000 (Illumina, Inc.) fol-
lowed the manufacturer’s manual.
Read Alignment
Whole genome DNA sequencing reads from ﬁve PCas, four
ATs, and ﬁve Bs were aligned by Burrows-Wheeler Aligner3
version 1.4.1 against the University of California, Santa Cruz,
hg19 human reference genome, allowing amaximal two-base
mismatches per (100-nucleotide) read. After alignment, the
average coverage of whole genome was >30 for all 14
samples. Picard tool (http://picard.sourceforge.net, last
accessed October 11, 2013) was applied to remove duplicate
reads after the alignment. RNA-seq reads (from ﬁve Ts, four
matched ATs, and four organ donor prostate samples) were at
an average of 1333 coverage. A maximum of two mis-
matches per read was allowed.
Fusion Transcript Detection
To identify fusion transcript events, we applied the Fusion-
catcher version 0.97 algorithm7 to the RNA-seq samples.
Embedded in Fusioncatcher, BOWTIE and BLAT were used
to align sequences to the reference genome. The preliminary2841
Table 1 Primer Sequences for RT-PCR
Gene(s) Forward Reverse
TMEM135-CCDC67 50-TTGGCATGATAGACCAGTCCC-30 50-CAGCACCAAGGGAATGTGTAG-30
Mtor-TP53BP1 50-TTGGCATGATAGACCAGTCCC-30 50-CAGCACCAAGGGAATGTGTAG-30
TRMT11-GRIK2 50-GCGCTGTCGTGTACCCTTAAC-30 50-GGTAAGGGTAGTATTGGGTAGC-30
CCNH-C5orf30 50-CCAGGGCTGGAATTACTATGG-30 50-AAGCACCAGTCTGCACAATCC-30
SLC45A2-AMACR 50-TTGATGTCTGCTCCCATCAGG-30 50-TGATATCGTGGCCAGCTAACC-30
KDM4B- AC011523.2 50-AACACGCCCTACCTGTACTTC-30 50-CTGAGCAAAGACAGCAACACC-30
MAN2A1-FER 50-TGGAAGTTCAAGTCAGCGCAG-30 50-GCTGTCTTTGTGTGCAAACTCC-30
LRRC59-FLJ60017 50-GTGACTGCTTGGATGAGAAGC-30 50-CCAGCATGCAGCTTTTCTGAG-30
TMPRSS2-ERG 50-AGTAGGCGCGAGCTAAGCAGG-30 50-GGGACAGTCTGAATCATGTCC-30
ACTB (b-Actin) 50-TCAAGATCATTGCTCCTCCTGAGC-30 50-TGCTGTCACCTTCACCGTTCCAGT-30
Yu et allist of candidate fusion transcripts is ﬁltered in Fusioncatcher
on the basis of the existing biological knowledge of the
literature, including the following: i) if the genes are known to
be the other’s paralog in Ensembl, ii) if one of the fusion
transcripts is the partner’s pseudogene, iii) if one of the fusion
transcripts is micro/transfer/small-nuclear RNA, iv) if the
fusion transcript is known to be a false-positive event (eg,
Conjoin gene database8), v) if it has been found in healthy
samples (Illumina Body Map 2.0; http://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-513, last accessed
September 22, 2013), and vi) if the head and tail genes are
overlapping with each other on the same strand. Fusion genes
were visualized with CIRCOS software version 0.66 (BC
Cancer Research Centre, Vancouver, British Columbia,
Canada) (Supplemental Figure S1).9
Machine Learning Techniques to Predict Recurrence
Status
Eight fusion genes from ﬁve tumor samples validated by RT-
PCR, Sanger sequencing, and ﬂuorescence in situ hybridization
(FISH) analyses were used as features to predict nonrecurrence
versus recurrence and the nature of the recurrence (PSADT,<4
versus 15 months or nonrecurrent). We applied linear
discriminant analysis (LDA) to construct the prediction model.
In light of relatively rare occurrence of the fusion transcripts
(4.4% to 9.0%) in our 90-sample Pittsburgh training cohort, we
also applied a simple prediction rule on the basis of the presence
in any subset of the eight fusiongenes (ie, a patient is predictedas
recurrence if any fusion transcript in a designated subset exists).
Leave-one-out cross validation was ﬁrst applied in the 90-
sample Pittsburgh training cohort to construct the model and
estimate the accuracy.Themodelwith thehighestYouden index
(sensitivity þ speciﬁcity  1)10 is selected from the training
cohort, and is then evaluated in an 89-sample Pittsburgh test
cohort, a 21-sample Stanford test cohort, and a 30-sample
Wisconsin test cohort. To compare the statistical signiﬁcance
of the area under the curve (AUC) difference between two
models, a bootstrap test is used to generate P values.11 To
compare the accuracy of twomodels, a test for equal proportions
using prop.test in R (http://www.r-project) was applied.
Todemonstrate the potential translational predictive value of
these fusion transcripts, information on nomogram-estimated,28425-year, prostate-speciﬁc antigen (PSA)efree survival proba-
bility and Gleason scores of the patients was incorporated into
our prediction models. The following models were generated:
i) eight fusion transcripts alone, ii) Gleason scores alone, iii)
nomogram values alone, iv) Gleason scores plus eight fusion
transcripts, and v) nomogram values plus eight fusion tran-
scripts. Complete information on prediction accuracy, sensi-
tivity, speciﬁcity, and Youden index for these eight models is
available in Supplemental Tables S2eS13.
RT-PCR and FISH
Double-stranded cDNA was synthesized as described pre-
viously.12,13 PCR assays were performed with the primers
indicated in Table 1 using the following conditions: 94C
for 5 minutes, followed by 30 cycles of 94C for 30 sec-
onds, 61C for 1 minute, and 72C for 2 minutes. The
procedures of probe preparation (Supplemental Table S5)
and FISH were described previously.14,15
Results
Fusion Transcripts Discovered by RNA and Whole
Genome Sequencing
To identify fusion transcripts, analysis of RNA sequencingwas
performed on ﬁve PCa samples. A total of 76 RNA fusion
events were identiﬁed using the Fusioncatcher7 program.
Thirteen of these fusion events were conﬁrmed by genome
sequencing.Tocontrol for tissue-basednormal fusion transcript
events, fusion transcripts present in any of the four age-matched
organ donor prostate tissues were eliminated. Furthermore,
fusion transcripts with<20 kb between each element and read
in the cis-direction were also eliminated. As a result of this
ﬁltering, 28of76 fusion transcript eventswere identiﬁed asPCa
speciﬁc (Supplemental Table S6 and Supplemental Figure S1).
Among these fusion events, TMPRSS2-ERG, the most com-
mon PCa fusion transcript,16e18 was found in two PCa sam-
ples. Most of the fusion events identiﬁed were novel. No
fusion transcripts were identiﬁed in any of the AT samples,
suggesting the somatic nature of these fusion transcripts. To
validate these fusion transcripts, RT-PCR was performed
using primers speciﬁc for fusion transcript regions encom-
passing the fusion breakpoints, and the PCR products wereajp.amjpathol.org - The American Journal of Pathology
Figure 1 Unique fusion gene events. Miniature diagrams of genome of the fusion genes, the transcription directions, the distances between the joining
genes, and the directions of the fusions. Representative sequencing chromograms of fusion transcripts. The joining gene sequences are indicated. Diagrams of
translation products of fusion transcripts are given. Blue head, gene translation product; red tail, gene translation product; orange, novel translation products
due to frameshift or translation products from a nongene region. UTR, untranslated region.
Signature Fusion Genes for Prostate Cancersequenced. Eight of these fusion transcript events were vali-
dated through sequencing (Figure 1).
Five of the eight fusion events resulted in truncation of a
head gene and frameshift in translation of a tail gene. One of
the fusion transcripts produced a truncated cyclin H and an
independent open reading frame of a novel protein whose
function is not known. Two fusion events, however, areThe American Journal of Pathology - ajp.amjpathol.orgpredicted to produce chimeras that possibly retain at least
partial function of both genes. For example, a fusion tran-
script between the N-terminus 703 amino acids of a-man-
nosidase 2A (MAN2A1) and the C-terminus 250 amino acids
of FER, a feline tyrosine kinase, retains the glycoside hy-
drolase domain of MAN2A1 but replaces the mannosidase
domain with the tyrosine kinase domain from FER. Another2843
Figure 2 FISH suggests genome recombination in prostate cancer cells. Schematic diagram of MAN2A1 and FER (A), SLC45A2 and AMACR (B), MTOR and
TP53BP1 (C), GRIK2 and TRMT11 (D), LRRC59 and FLJ60017 (E), TMEM135 and CCDC67 (F), CCNH and C5orf30 (G), and KDM4B and AC011523.2 (H) genome
recombination and FISH probe positions. Representative FISH images are shown for normal prostate epithelial cells and cancer cells positive for MAN2A1-FER
(A), SLC45A2-AMACR (B), MTOR-TP53BP1 (C), TRMT11-GRIK2 (D), LRRC59-FLJ60017 (E), TMEM135-CCDC67 (F), CCNH-C5orf30 (G), and KDM4B-AC011523.2 (H)
fusions. Orange dots denote probe 1; green dots, probe 2. Break-apart signals are indicated by orange arrows; fusion joining signals, green arrows.
Yu et alfusion transcript couples 5 of 10 transmembrane domains of
the membrane transporter protein SLC45A2 with the methyl-
acyl CoA transferase domain from AMACR. Interestingly,
both MAN2A1-FER and SLC45A2-AMACR fusions are in
the trans-direction, eliminating the possibility of a fusion2844event from simple chromosome deletion or collapse of an
extremely large RNA transcript.
The most frequent fusion events observed in PCa were
TRMT11-GRIK2 [22 (7.9%) of 279] and SLC45A2-AMACR
[20 (7.2%) of 279] (Supplemental Figures S2-S4). TRMT11-ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Fusion transcripts expressed in
prostate cancer. A: Distribution of eight indicated
fusion transcripts in 213 prostate cancer samples
from UPMC, 30 samples from Stanford University
Medical Center, and 36 samples from University of
Wisconsin Madison Medical Center. Samples from
patients who experienced recurrence were indi-
cated with light gray (PSADT 15 months), dark
gray (PSADT <4 months), or intermediate gray
(PSADTZ 5 to 14 months); samples from patients
who have no recurrence for at least 5 years, green;
and samples from patients whose clinical follow-up
is ongoing but <5 years, white (undetermined). B:
Correlation of fusion transcript events with pros-
tate cancer recurrence. The percentage of prostate
cancer experiencing recurrence from samples pos-
itive for fusion transcripts is plotted for each
fusion transcript from speciﬁed cohorts.
Signature Fusion Genes for Prostate CancerGRIK2 fusion represents a giant truncation of TRMT11, a
tRNA methyltransferase, and elimination of GRIK2, a
glutamate receptor but reported to possess tumor-suppressor
activity.19 Indeed, when GRIK2 expression was examined
in 14 TRMT11-GRIK2epositive PCa samples, it was un-
detectable, whereas it was detected in organ donor prostate
samples (Supplemental Figure S5). Only 4 of 14 samples
with TRMT11-GRIK2 expressed full-length TRMT11 tran-
scripts. Thus, the fusion event of TRMT11-GRIK2 likely
produces a loss of function.
FISH Suggests Genome Recombination Underlying
Fusion Transcript Formation
To investigate the mechanism of these fusion events, FISH
was performed on PCa tissues where the fusion transcripts
were present. By using the probes surrounding the MAN2A1
breakpoint, a physical separation of signals between 50 and 30
MAN2A1 in cancer cells containing the fusion was observed,
whereas the wild-type alleles in normal prostate epithelial
cells showed overlapping ﬂuorescent signals (Figure 2).
Similar break-apart hybridization occurred in SLC45A2-
AMACRepositive PCa samples (Figure 2B). These ﬁndings
indicate that MAN2A1-FER and SLC45A2-AMACR fusions
are the result of chromosomal recombination events and
validate the fusion transcripts found by RNA-seq. Interest-
ingly, in PCa cells containing break-apart signals ofMAN2A1,
only 31% of the cells retained the 30 end signal, suggesting
that the recombination event results in truncation of theThe American Journal of Pathology - ajp.amjpathol.orgC-terminus ofMAN2A1 inmost PCa cells. A similar collateral
loss of the N-terminus of AMACR was found in PCa cells
expressing the SLC45A2-AMACR fusion transcript (29%
retaining the N-terminus signal of AMACR). Other FISH
analyses conﬁrmed that genome translocations occur in can-
cer cells expressing TRMT11-GRIK2, MTOR-TP53BP1,
LRRC59-FLJ60017, TMEM137-CCDC67, CCNH-C5orf30,
andKDM4B-AC011523.2 fusion transcripts (Figure 2, CeG).
These fusion transcripts are either separated widely on a
single chromosome (TRMT11-GRIK2, TMEM135-CCDC67,
CCNH-C5orf30, and KDM4B- AC011523.2) or located on
separate chromosomes (MTOR-TP53BP1 and LRRC59-
FLJ60017). The overlapping signals of hybridizations in
PCa cells offered additional validation of these fusion events.
Finally, genomic breakpoints were identiﬁed in three fusion
pairs through Sanger sequencing of the cancer genomic
DNA (CCNH-C5orf30, TMEM135-CCDC67, and LRRC59-
FLJ60017) (Supplemental Figure S6).
Fusion Transcripts Associate with PCa Recurrence
To investigate the clinical and biological signiﬁcance of the
fusion transcripts, their presence was assessed in PCa speci-
mens obtained from 213 men and in histologically conﬁrmed
benign prostate tissues obtained from 10 organ donors free of
urological disease (aged 20 to 70 years). For 179 of the 223 PCa
samples, clinical outcome data after radical prostatectomy were
available, and 81 had no detectable PSA recurrence after a
minimum of 5 years of follow-up, whereas 98 developed2845
Figure 4 Fusion genes predict recurrence of prostate cancer. A: Scheme of training and validation steps in building fusion gene prediction models for
prostate cancer recurrence and short PSADT. (I) The algorithm of fusion gene prediction of prostate cancer recurrence and PSADT<4 months was obtained from
90 randomly assigned prostate cancer samples from UPMC. (II) The algorithm was then applied to 89 samples from UPMC. (III) The algorithm was applied to 21
samples from Stanford University Medical center. (IV) The algorithmwas applied to 33 samples fromUniversity of Wisconsin Madison Medical Center. B: Prediction
rate of prostate cancer recurrence and PSADT4 months using prostate cancer sample cohorts from UPMC, Stanford Medical Center, and University of Wisconsin
Madison Medical Center, on the basis of the algorithm obtained from the 90etraining sample cohort. C: Kaplan-Meier analysis of patients who were positive for
any of TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67, and CCNH-C5orf30 versus those who were negative for these fusion
events. Kaplan-Meier analysis of prostate cancer sample cohort from UPMC and Stanford University Medical Center; P value is indicated for the signiﬁcant
difference in survival between the group that is positive for at least one fusion transcript and the group that is negative for at least one fusion transcript.
Yu et albiochemical recurrence (deﬁned as a measurable PSA0.2 ng/
mL). In the patients without recurrence, only 7.4% (6/81) pri-
mary prostate cancers expressed one of the fusion transcripts. In
contrast, 52% (51/98) primary prostate cancers expressed at
least one fusion in patients who developed biochemical recur-
rence (Figure 3 and Supplemental Figure S2A). No fusion
transcripts were detected in benign prostate tissues obtained
from healthy organ donors (Supplemental Figure S2B). Three
fusion events were observed exclusively in recurrent PCa after
radical prostatectomy (TRMT11-GRIK2,MTOR-TP53BP1, and
LRRC59-FLJ60017) (Figure 3, A and B).
Fisher’s exact test showed a signiﬁcant difference in recur-
rent status between patients with at least one of the eight fusion
transcripts and those without this transcript (PZ 6.8 1016).
In the combined University of Pittsburgh Medical Center
(UPMC), Stanford, and Wisconsin data sets, 91% (69/76) of
patients positive for one of the fusion transcripts experienced
prostate cancer recurrence in 5 years after prostate resection.On
the basis of the hypothesis that the presence of at least one of the
eight fusion transcripts would indicate a recurrence for a
prostate cancer patient, a PCa prediction model was built and
tested, using 90 randomly selected PCa samples from UPMC
(training set). This training cohort yielded an accuracy of PCa
recurrence prediction of 71%, with 89% speciﬁcity and 58%2846sensitivity (P < 0.005) (Supplemental Figure S7A and
Supplemental Table S7). When this model was applied to a
separate cohort of 89 samples (test set), the model correctly
predicted recurrence in 70% of patients. To further validate this
model, we tested its performance in a 30-patient (21 with
qualiﬁed clinical follow-up) cohort from Stanford University
Medical Center and a 36-patient (30 with qualiﬁed clinical
follow-up) cohort from University of Wisconsin Madison
Medical Center (Figure 3 and Supplemental Figures S4 and
S5). Once again, the model correctly predicted recurrence,
with 76.2% accuracy, 89% speciﬁcity, and 67% sensitivity on
the PCa cohort from Stanford, and 80% accuracy, 100%
speciﬁcity, and 63% sensitivity on the Wisconsin cohort
(Supplemental Table S8).
In itself, recurrence does not signal an aggressive prostate
cancer, because many patients with PSA recurrence do not
develop metastases or die from their disease. A PSADT <4
months after radical prostatectomy is strongly associated with
the early development of metastatic disease and prostate
cancerespeciﬁc death, whereas these events are rare and
remote in men with a PSADT>15 months.20,21 The presence
of one or more fusion transcripts in the PCa tissue showed a
strong association with PSADT<4 months (PZ 6 109).
To examine whether these fusion transcripts have prognosticajp.amjpathol.org - The American Journal of Pathology
Figure 5 Combining status of fusion transcript and clinical/pathological parameter to improve prediction of prostate cancer recurrence. A: Combining
Gleason’s grading and the status of eight fusion transcripts in prostate cancer samples using LDA technique to predict the recurrence of prostate cancer. ROC curve
analysis of Gleason alone or Gleason plus the presence of fusion transcripts using LDA technique in the prediction of prostate cancer recurrence; P value
(permutation test) is indicated for the signiﬁcant difference between the ROC curve generated by Gleason alone and the curve generated by Gleason plus the
presence of fusion transcripts using LDA technique. Kaplan-Meier analysis of PSA-free survival of prostate cancer patients with Gleason score8 versus<8 from
combined UPMC testing, Wisconsin, and Stanford data sets; P value (log-rank test) is indicated for the signiﬁcant difference in survival between the group that
has Gleason score8 and the group that has score<8. Kaplan-Meier analysis of PSA-free survival of prostate cancer patients with Gleason score8 or positive for
any of the eight fusion transcripts in the prostate cancer samples versus those with Gleason score<8 and negative for fusion transcripts using LDA from combined
UPMC testing, Wisconsin, and Stanford data sets. P value (log-rank test) is indicated for the signiﬁcant difference in survival between the group that is positive for
at least one fusion transcript or has Gleason score8 and the group that is negative for fusion transcript and has Gleason score<8. B: Combining nomogram and
the status of eight fusion transcripts in prostate cancer samples using LDA technique to predict the recurrence of prostate cancer. ROC analysis of nomogram alone
or nomogram plus the presence of fusion transcripts using LDA technique in the prediction of prostate cancer recurrence. P value (permutation test) is indicated
for the signiﬁcant difference between the ROC curve generated by nomogram alone and the curve generated by nomogram plus the presence of fusion transcripts
using LDA technique. Kaplan-Meier analysis of PSA-free survival of prostate cancer patients with probability >88 versus 88 from combined UPMC testing,
Wisconsin, and Stanford data sets; P value (log-rank test) is indicated for the signiﬁcant difference in survival between the group that has probability >88 PSA-
free survival and the group that has 88 probability. Kaplan-Meier analysis of PSA-free survival of prostate cancer patients with nomogram 88 or positive for
any of the eight fusion transcripts in the prostate cancer samples versus those >88 and negative for fusion transcripts using LDA from combined UPMC testing,
Wisconsin, and Stanford data sets. P value (log-rank test) is indicated for the signiﬁcant difference in survival between the group that is negative for fusion
transcript and has probability >88 PSA-free survival and the group that is positive for fusion transcript or has 88 probability.
Signature Fusion Genes for Prostate Cancervalue for PCa clinical outcome, a prediction model was built
using the optimized weight of each fusion transcript calcu-
lated by LDA classiﬁer on the basis of the P value of each
fusion transcript with short PSADT. The panel of eight fusion
transcripts correctly predicted 74.4% for PSA doubling time
in the 90-sample training cohort (Supplemental Figure S6).
When the same algorithmwas applied to a separate 89-sample
test set from UPMC and a 21-sample cohort from Stanford
UniversityMedical Center, the prediction rate for PSADT4
months was found to be 78% and 71%, respectively
(Figure 4B). To examine the impact of fusion transcripts on
patients’ PSA-free survival, a Kaplan-Meier analysis was
performed on the PCa cohort from University of Pittsburgh.
Patients (84.2%) had an observed disease recurrence within 5
years of radical prostatectomy if they carried any of the eight
fusion transcripts (Figure 4C). No patient survived 5 yearsThe American Journal of Pathology - ajp.amjpathol.orgwithout recurrence if his or her primary PCa contained a
TRMT11-GRIK2 or MTOR-TP53BP1 transcript fusion. In
contrast, 68% of the patients were free of disease recurrence if
none of the fusion transcripts was detected in their primary
PCa. Similar ﬁndings were also identiﬁed in the Stanford
cohort: 88.9% of the patients experienced recurrence of PCa if
they carried any fusion transcript, whereas 66.7%were free of
the disease recurrence if they were negative for the transcript.
Combining Detection of Fusion Transcripts and
Clinical/Pathological Parameters Improves Prediction
Rate of Prostate Cancer Recurrence
Prostate cancer samples with at least one fusion transcript
correlate with more advanced stage of prostate cancer
(PZ 0.004), lymph node involvement status (PZ 0.005), and2847
Yu et allower nomogram scores (P Z 0.0003) (Supplemental Table
S9). Gleason grading alone produces a prostate cancer recur-
rence prediction rate of 61.1%, with 85.7% speciﬁcity and
39.6% sensitivity in the 90-sample UPMC training cohort,
when aGleason score8was used as cutoff to predict prostate
cancer recurrence. The Gleason model yielded prediction ac-
curacy ranging from 57% to 60% in three separate testing
cohorts (Supplemental Tables S10 and S11). However, when
fusion transcript status was combined with Gleason grade8,
improvement of prediction was found for all four cohorts:
72%, 74%, 76%, and 90% for theUPMC training, UPMC test,
Stanford, and Wisconsin cohorts, respectively. The receiver
operating characteristic (ROC) curve showed a signiﬁcantly
larger AUC (0.84 versus 0.67; PZ 6.6 107) and a higher
testing accuracy (77.7% versus 59.7%; P Z 0.0019)
(Figure 5A)whenGleason scorewas combinedwith detection
of any of the eight fusion transcripts. Similarly, nomogram
prediction of prostate cancer recurrence has the best accuracy
of 76%, with 68.8% sensitivity and 83.3% speciﬁcity in the
analysis of a 90-sample UPMC training cohort (Supplemental
Table S12). When this model was applied to UPMC testing,
Stanford, and Wisconsin cohorts independently, the results
showed that the prediction accuracy ranged from 60% to 75%
among the three cohorts (Supplemental Table S13). When
nomogram was combined with the status of eight fusion
transcripts using the LDA technique to build a classiﬁer, the
accuracy of prediction improves to 81% to 83% among the
testing cohorts (Supplemental Table S13). The ROC curve
showed an increase of AUC from 0.76 to 0.87 (PZ 0.0001)
and an improvement of accuracy from 69% to 81%
(P Z 0.026) (Figure 5B). As a result, we concluded that
classiﬁer combining nomogram and the eight fusion gene
panel generated the best prediction accuracy, which out-
performs each diagnostic tool alone.
Discussion
Transcriptome sequencing revealed numerous fusion RNA
transcripts occurring not just in PCabut also in benign adjacent
tissues andhistologically normal organ donor prostate samples
(Supplemental Table S14). Whether these transcripts encode
functional fusion proteins is not known. Deep sequencing of
the whole genome and RNA revealed a signiﬁcant number of
prostate cancerespeciﬁc fusion transcripts. These fusions are
not detectable in either benign organ donor prostate or benign
prostate tissues from PCa patients. Most of these fusion tran-
scripts appear to express in low abundance, with only an
average of 6.6 reads of these fusion transcripts detected in
>1333 sequencing. Indeed, when the coverage was reduced
to 600 in simulation studies, only MTOR-TP53BP1 was
detected consistently. One general characteristic of these
fusion transcripts is that they either have a large distance be-
tween the gene targets or are oriented in trans-, features that
could only occur as a result of chromosome recombination
events. In either scenario, the fusions must be the product of
signiﬁcant structural DNA rearrangements.2848Although the association between the eight novel fusion
transcripts and prostate cancer recurrence is striking, the bio-
logical roles of these fusion transcripts are not yet elucidated.
Given the known function of the genes contributing to the
fusion transcripts, their formation may have impact on several
cell pathways, such as RNA stability22 (TRMT11-GRIK2),
protein glycosylation23 (MAN2A1-FER), cell cycle pro-
gression24e26 (CCNH-C5orf50 and MTOR-TP53BP1), ﬁbro-
blast growth factor nuclear import27 (LRRC59-FLJ60017),
histone demethylation28 (KDM4B-AC011523.2), and fatty
acid metabolism29 (SLC45A2-AMACR). Many of these path-
ways appear to be fundamental to cell growth and survival.
Two of the fusion genes are of particular interest:
MAN2A1-FER and SLC45A2-AMACR. First, MAN2A1 is a
mannosidase critical in glycosylation of proteins.23 It is
usually located in the Golgi apparatus. The truncation in
MAN2A1-FER replaces the mannosidase domain with a
tyrosine kinase domain from FER,30 whereas it leaves the
glycosyl transferase domain intact. The chimera protein
likely loses the mannosidase function. The new kinase
domain in MAN2A1-FER may confer the chimera protein
a tyrosine kinase activity. Thus, the impact of this fusion
gene could be profound: abnormal glycosylation and
phosphorylation in hundreds of secreted or plasma mem-
brane proteins. It may affect cell-cell interactions and signal
transduction and generate a new immune response to the
cancer cells. Second, AMACR is a racemase that catalyzes
2R stereoisomers of phytanic and pristanic acids to their S
counterparts. AMACR is essential for b oxidation of branch
fatty acid in mitochondria. SLC45A2 is a transmembrane
solute carrier known for its protective role in melanoma.
SLC45A2-AMACR chimeric protein has ﬁve transmembrane
domains of SLC45A2 truncated and is replaced with a
largely intact racemase. SLC45A2-AMACR also loses the
mitochondria target site in AMACR. Presumably, the fusion
protein would be located in the plasma membrane. It is of
interest that most of the prostate cancer samples with
SLC45A2-AMACR fusion proved highly aggressive. Iden-
tiﬁcation of the signaling pathways of this chimeric protein
may gain critical insight into the behavior of prostate
cancer.
Although the prevalence of each fusion transcript in
prostate cancer samples is low (ranging from 2.9% to 7.9%),
up to 60% of prostate cancers that later recurred and had a
short PSADT were positive for at least one of these fusion
transcripts. The speciﬁcity of these fusion transcripts in
predicting prostate cancer recurrence appears remarkably
high, ranging from 89% to 100% among four separate
prediction cohorts. There were no long-term recurrence-free
survivors if the primary tumor contained TRMT11-GRIK2,
MTOR-TP53BP1, or LRRC59-FLJ60017 fusion transcripts.
To our knowledge, this is the ﬁrst report showing that a
set of fusion transcripts is strongly associated with PCa
prognosis. This set of fusion transcripts is of signiﬁcant
clinical value because of its high prediction rate of prostate
cancer clinical outcomes when they are positive, and theirajp.amjpathol.org - The American Journal of Pathology
Signature Fusion Genes for Prostate Cancerroles in improving the existing clinical prediction models
when combining these fusion transcripts with Gleason’s
grading or nomogram. Addition of TMPRSS2-ERG does not
improve the prediction model (Supplemental Tables S7, S8,
S11, and S13). This discovery may prove useful in clinical
practice given the current limitations of serum PSA, Glea-
son grading, and clinical stage to accurately predict disease
course. If these fusion transcripts are found to have a bio-
logical role in prostate cancer progression, this may provide
new targets for therapeutic intervention.
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